GlaxoSmithKline and Nabi Biopharmaceuticals entered an exclusive worldwide option and licensing agreement for nicotine conjugate candidate vaccine NicVAX, an investigational vaccine for the treatment of nicotine addiction and the prevention of smoking relapse, as well as for the development of a second generation nicotine vaccine. Nabi will receive $40 million upfront and GSK will have an option to exclusively in-license NicVAX on a worldwide basis and a license to develop follow-on next-gen ...